argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
630.00
+14.23 (2.31%)
At close: Dec 23, 2024
argenx SE Revenue
argenx SE had revenue of $588.88M in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
1.91B
Revenue Growth
+85.56%
P/S Ratio
n/a
Revenue / Employee
1.66M
Employees
1,148
Market Cap
37.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
argenx SE News
- 7 days ago - Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - Benzinga
- 4 weeks ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 5 weeks ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 5 weeks ago - (ARGX) - Analyzing argenx's Short Interest - Benzinga
- 6 weeks ago - This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 6 weeks ago - Argenx upgraded at Wolfe on myasthenia gravis dominance - Seeking Alpha
- 6 weeks ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire